Amycretin dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
Amycretin is Novo Nordisk's single drug that works on both GLP-1 and amylin, a fullness hormone. It comes as a pill and a shot. It took weight off strongly in early studies and is now in large final-stage studies.
Evidence grade for Amycretin: Moderate. The rule: at least one finished study in people, and at least 100 people who took it. The sum on this page: 1 completed trial, 125 people given it. A grade counts how much has been done to people, not whether it works.
- People given it
- 125
- Human studies
- 1
- Found nothing
- 0
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
1 completed trial, 125 people given it
2 effects reported, 1 unwanted, 1 wanted, by people using it, not a trial
Goal pages: Fat loss and metabolism
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Amycretin is one drug that hits two fullness signals, GLP-1 and amylin. CagriSema does the same job with two drugs. Novo Nordisk is making it as a weekly shot and as a pill. It is not approved. Large final-stage studies began in 2026.
What people take it for
- A lot of weight loss from one drug.
- Weight loss with type 2 diabetes.
- A pill form, down the road.
What studies in people showed
In an early study, 125 people took the shot or a dummy shot for 36 weeks. On the drug they lost 22 to 24 percent of their weight. The dummy group gained a little. Stomach upset was common. In a mid-stage study in type 2 diabetes, people lost about 14.5 percent in 36 weeks. A large study of 1,150 people began in February 2026. Its main result is due in 2029.
What people report
Reports, not study results
The good
- In the studies on this page, people lost around a quarter of their weight in nine months.
The bad
- Stomach upset was common in the early study on this page. That is the main reason people quit drugs like this.
Where these come from: The results and the stomach upset are from the studies on this page. We have not collected forum or user reports for this drug yet.
My bottom line
Big early numbers in 125 people. That is a start, not an answer. If you use drugs like this, the muscle you keep matters as much as the fat you lose, so lift.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Measured in people
Goals Amycretin has been tested for in people, biggest studies first. We count only what the studies on this page say, so the real numbers may be higher.
- Losing weight125 people · 1 study
35 of the 36 indexed goals have no study of any kind behind Amycretin
No study in people, animals or cells on this page reports a result for these. That does not prove Amycretin does nothing for them. It does mean anything you have heard about Amycretin and one of these did not come from a study cited here.
Show full evidence
What is Amycretin?
Amycretin is Novo Nordisk's single drug that works on both GLP-1 and amylin, a fullness hormone. It comes as a pill and a shot. It took weight off strongly in early studies and is now in large final-stage studies.
Amycretin is a Novo Nordisk drug that packs two appetite signals, GLP-1 and amylin, into one molecule. The goal is to match a two-drug combo with a single drug. It is being made as a pill and as a shot. In an early study of the shot, 125 people lost 22 to 24 percent of their weight in 36 weeks. People on a dummy shot gained a little. Stomach upset was common. In a mid-stage study in people with type 2 diabetes, the shot took off about 14.5 percent in 36 weeks. Large final-stage studies, called AMAZE, began in February 2026. It is not approved.
How does Amycretin work?
One molecule turns on both the GLP-1 and amylin signals. Each one tells the brain you are full, in a different way.
The evidence, in charts
Fig. 1a · how many people
125people, across 1 study in people cited here
| Study | People | Share |
|---|---|---|
| The Lancet 2025 | 125 | 100% |
The whole total is one study of 125. Counts are the number of people each study on this page says it signed up. That includes studies that only watched people and gave nobody the compound. 2 more studies in people give no headcount and are not counted here. Studies still signing people up are left out, and only studies cited on this page are counted.
Fig. 1b · evidence mix
All 3 sources here are studies in people.
- Study in people · done in people3100%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
Sources here come from just two years, 2025 and 2026.
Too few different years on this page to draw a timeline.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Peptide
- Molecule weight
- Not disclosed
- Half-life
- Stated in words, not a numbersee the exact wording below
- Chain length
- None on file
Half-life as stated on file: Supports weekly (injectable) dosing
No amino acid sequence is on file for Amycretin, so none is drawn rather than guessed from a name.
The studies we cite
- Study in people2025Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study
Weight fell by roughly a quarter in nine months, which is as much as anything in this class has managed. 125 people took one of two doses or a dummy, and the dummy group gained a little. Stomach upset was common, and that matters, because it is the main reason people abandon these drugs. An early trial in 125 people is a promising start, not a settled answer.
125 participants: weight fell 22.0% (20 mg) and 24.3% (60 mg) at 36 weeks versus about 1% to 2% gain with placebo; GI events common.
- Study in people2025Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1 trial
This was the first time the drug was given to a human being. The study asked whether it was safe and what the body did with it, and it picked up an early hint of weight loss along the way. First in human studies are not built to show that a drug works. This one did its actual job, which was to clear the way for larger trials.
Oral amycretin first-in-human study establishing safety and early weight-loss signal.
- Study in people2026AMAZE 1: a research study investigating how well the medicine NNC0487-0111 helps people with excess body weight lose weight
Nothing has been found here yet. This is a large trial that began signing people up in February 2026 and is aiming for 1,150 participants. Its main answer is not due until the middle of 2029. It is listed because knowing what is still being tested is part of knowing what is currently known.
Phase 3, 1,150 participants, started February 24, 2026, recruiting; primary completion mid-2029.
Where to buy Amycretin
No seller we track lists Amycretin yet. We read sellers’ public product lists every week, and this section fills in as soon as one does. Every seller, graded
Common questions
Has Amycretin been tested in people?
Yes. 125 people given it across 1 completed trial cited here, 0 of which found nothing. Amycretin is Novo Nordisk's single drug that works on both GLP-1 and amylin, a fullness hormone. It comes as a pill and a shot. It took weight off strongly in early studies and is now in large final-stage studies.
What is the Amycretin dosage?
No human dose established. Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose. 1 completed trial, 125 people given it
Is Amycretin FDA-approved?
Investigational (the final-stage AMAZE studies started February 2026)
How is amycretin different from CagriSema?
CagriSema is two separate drugs, cagrilintide and semaglutide, in one shot. Amycretin puts the GLP-1 and amylin action into a single molecule.
Latest reading on Amycretin
Blog posts about Amycretin, newest first.
- Metabolic / Sep 27, 2026 / 9 minMariTide (Maridebart Cafraglutide): The Once-Monthly GLP-1 Agonist and GIP Blocker, Explained
- Metabolic / Sep 27, 2026 / 9 minCagrilintide: The Amylin Half of CagriSema, and Why People Search 'Cagrilintide with Retatrutide'
- Metabolic / Sep 27, 2026 / 9 minRetatrutide vs Tirzepatide vs Semaglutide vs the Pill: The 2026 GLP-1 Field Guide